Market
Major public health funding for AI antivenom research by mid-2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Press releases or announcements from public health organizations or research institutions
Story
AI-Designed Proteins Neutralize Snake Venom Toxins, Achieving 80-100% Survival Rates in Mice Tests on January 15 by David Baker
Jan 15, 2025, 02:00 PM
Researchers have successfully utilized artificial intelligence (AI) to design proteins that can neutralize toxins from snake venom, a breakthrough that could lead to the development of more effective and safer antivenoms. A study published on January 15 in the journal Nature, led by Nobel Laureate David Baker's team, demonstrated that these AI-designed proteins achieved survival rates of 80-100% in tests conducted on mice. This innovative approach not only offers a faster and cheaper method for creating antivenoms but also addresses the urgent need for improved treatments for snakebite envenoming, which poses a significant public health challenge globally. The research highlights the potential of generative AI in drug development, particularly in the design of therapeutic proteins against neglected tropical diseases.
View original story
Similar markets
11-15 species • 25%
1-5 species • 25%
6-10 species • 25%
More than 15 species • 25%
North America • 25%
Asia • 25%
Africa • 25%
South America • 25%
Less than $500 million • 25%
More than $1.5 billion • 25%
$1 billion to $1.5 billion • 25%
$500 million to $999 million • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Other • 25%
Roche • 25%
Johnson & Johnson • 25%
Google Research • 25%
Defense Advanced Research Projects Agency (DARPA) • 25%
National Science Foundation (NSF) • 25%
Other • 25%
Grant postponed • 25%
Under review • 25%
Grant canceled • 25%
Grant awarded • 25%
